Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.
|Videos|December 15, 2021
iPLEDGE and Isotretinoin: What Happened?
Author(s)Linda Stocum, Associate Editor
In this video interview, Klint Peebles, MD, FAAD, co-chair of the AAD LGBTQ/SGM Expert Resource Group, explains what happened with the iPLEDGE website.
Advertisement
In this first part of a video interview with Klint Peebles, MD, FAAD, co-chair of the AAD LGBTQ/SGM Expert Resource Group, Peebles explains the history of iPLEDGE and what may have led to the current difficulties that physicians, pharmacies, and patients are dealing with.
Advertisement
Related to this article
Benjamin Ungar, MD, moderated a recent Dermatology Times Case-Based Roundtable event on how to define severity, choose among JAK inhibitors, and monitor patients with alopecia areata.
Clinicians at a Dermatology Times Case-Based Roundtable, moderated by Chesahna Kindred, MD, debated when to escalate to oral JAK inhibitors for alopecia areata and how to counsel patients on timing, monitoring, and safety.
The joint AAD-HSF guideline issues 37 recommendations, including strong support for adalimumab, bimekizumab, infliximab, and secukinumab.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Dermatology’s growing focus on skin longevity demands clear definitions, validated outcomes, and rigorous evidence beyond anti-aging claims.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Disc Medicine reports the phase 3 APOLLO trial met all primary and secondary end points, with whole-blood PPIX reduced 41.4% vs placebo and an NDA resubmission planned by end of 2026.
Advertisement
Advertisement
Trending on Dermatology Times
1
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Skin Longevity Needs Evidence, Not Hype
4
Individualizing Systemic Therapy for Alopecia Areata Across Patient Cases
5